- Home
- NNAVW vs ITRM Comparison
NNAVW vs ITRM Comparison
Compare NNAVW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNAVW
- ITRM
- Stock Information
- Founded
- NNAVW 2007
- ITRM 2015
- Country
- NNAVW United States
- ITRM Ireland
- Employees
- NNAVW 96
- ITRM N/A
- Industry
- NNAVW Industrial Machinery/Components
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- NNAVW Industrials
- ITRM Health Care
- Exchange
- NNAVW Nasdaq
- ITRM Nasdaq
- Market Cap
- NNAVW N/A
- ITRM 40.0M
- IPO Year
- NNAVW N/A
- ITRM 2018
- Fundamental
- Price
- NNAVW $6.53
- ITRM $1.16
- Analyst Decision
- NNAVW
- ITRM Strong Buy
- Analyst Count
- NNAVW 0
- ITRM 2
- Target Price
- NNAVW N/A
- ITRM $7.00
- AVG Volume (30 Days)
- NNAVW 53.1K
- ITRM 583.9K
- Earning Date
- NNAVW 03-12-2025
- ITRM 08-13-2025
- Dividend Yield
- NNAVW N/A
- ITRM N/A
- EPS Growth
- NNAVW N/A
- ITRM N/A
- EPS
- NNAVW N/A
- ITRM N/A
- Revenue
- NNAVW $4,963,000.00
- ITRM N/A
- Revenue This Year
- NNAVW N/A
- ITRM N/A
- Revenue Next Year
- NNAVW N/A
- ITRM $270.19
- P/E Ratio
- NNAVW N/A
- ITRM N/A
- Revenue Growth
- NNAVW 43.44
- ITRM N/A
- 52 Week Low
- NNAVW $4.47
- ITRM $0.81
- 52 Week High
- NNAVW $4.70
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- NNAVW N/A
- ITRM 61.00
- Support Level
- NNAVW N/A
- ITRM $0.91
- Resistance Level
- NNAVW N/A
- ITRM $1.03
- Average True Range (ATR)
- NNAVW 0.00
- ITRM 0.05
- MACD
- NNAVW 0.00
- ITRM 0.01
- Stochastic Oscillator
- NNAVW 0.00
- ITRM 95.18
About NNAVW NextNav Inc. Warrant
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.